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The immunosuppressive action of regulatory T (Treg)
cells is one mechanism attributed to the limited success
of cancer immunotherapies with checkpoint blockers.
Two recent studies report distinct transcriptional profiles
of tumor-infiltrating Treg cells and expression of specific
molecules, suggesting novel strategies to overcome
resistance to cancer immunotherapy.function. However, although widely accepted to be im-Regulatory T cells in cancer immunotherapy
Oncology has been revolutionized by a paradigm shift in
the way we treat advanced and/or metastasized cancers.
Instead of targeting tumor cells using specific inhibitors,
immune cells are targeted to induce or enhance antitumor
immunity. Currently, the most promising cancer immuno-
therapy approach is the blockade of immune checkpoints,
which are inhibitory molecules that modulate the
amplitude and duration of immune responses [1]. Anti-
bodies that block checkpoint receptors, such as the cyto-
toxic T-lymphocyte-associated antigen 4 (CTLA4) and
programmed cell death protein 1 (PD1), have shown re-
markable clinical effects. However, durable responses to
checkpoint blockers have been obtained in only a fraction
of patients [1], suggesting that persistence of immunosup-
pressive mechanisms may contribute to intrinsic resistance
to cancer immunotherapy.
Cells in the tumor microenvironment attributed with
immunosuppressive activities include cancer-associated
fibroblasts, myeloid-derived suppressor cells, and CD4+
regulatory T (Treg) cells expressing the transcription
factor FOXP3. Specifically, Treg cells play an essential
role in suppressing aberrant immune responses against
self-antigens and anti-tumor immune responses. Treg
cells are potent suppressors of effector T cells, and,* Correspondence: zlatko.trajanoski@i-med.ac.at
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Treg cells have been associated with poor prognosis in a
number of cancers [2, 3]. Treg cells can suppress effector
T cells through different direct mechanisms, including
secretion of inhibitory cytokines, granzyme-mediated cy-
tolysis of effector T cells, and metabolic impairment of
effector T cells—for example, by depletion of
interleukin-12 (IL-12)—as well as indirect mechanisms
such as suppression of dendritic cell maturation and
plicated in tumor growth, the molecular phenotypes of
tumor-infiltrating Treg cells remain poorly characterized.
Identification of molecules expressed specifically in
intratumoral Treg cells through genome-wide/transcrip-
tomic analysis has the potential to reveal valuable new
targets for therapeutic intervention. Depletion of tumor-
infiltrating Treg cells targeting these molecules would
shift the balance from immune suppression to immune
activation towards tumor cells.Unique molecular fingerprints of tumor-
infiltrating regulatory T cells
So far, most of the knowledge of these immunosuppressive
cells has been derived from the study of peripheral blood
Treg cells, whereas a complete portrait of tumor-resident
Treg cells, including Treg-specific markers, is still lacking.
In a recent edition of Immunity, two independent studies,
led by Rudensky [4] and Pagani [5], shed light on the
features of Treg cells infiltrating common human cancers.
The Rudensky laboratory [4] characterized flow-
cytometry-sorted Treg cells from human breast carcinomas,
peripheral blood, and normal breast parenchyma using
RNA sequencing. Tumors with more aggressive pheno-
types, such as triple-negative breast cancers (TNBCs), con-
tained higher frequencies of Treg cells, which might imply
an active role for Treg cells in cancer progression. RNA-
sequencing analysis revealed marked transcriptomic differ-
ences between tumor- or tissue-resident Treg versus periph-
eral blood Treg cells, while the gene expression profiles
were highly comparable between Treg cells present in breastle is distributed under the terms of the Creative Commons Attribution 4.0
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residence, rather than the tumor environment, determines
the phenotype of infiltrating Treg cells. The gene expression
profiles did, however, reveal an enhanced activation of
tumor-infiltrating Treg cells compared to Treg cells present
in normal breast parenchyma and the upregulation of genes
involved in chemokine signaling and immune cell migra-
tion. In particular, the marked expression of chemokine re-
ceptor 8 (CCR8), a molecule implicated in the modulation
of immunogenicity in colorectal cancer (CRC) [6], was
identified as a unique feature of intratumoral Treg cells. This
was confirmed in Treg cells isolated from other types of
cancers, including CRC, lung cancer, melanoma, and angio-
sarcoma. Moreover, the authors found a strong negative as-
sociation between the ratio of CCR8/FOXP3-expressing
cells and patient survival.
The Pagani laboratory [5] used RNA sequencing to pro-
file human CD4+ Treg cells as well as T helper 1 and T
helper 17 cells infiltrating non-small-cell lung cancer
(NSCLC), CRC, and the respective matched normal tis-
sues, as well as peripheral blood Treg cells. Their results
show a large overlap of the expression profiles from tis-
sue- and tumor-resident Treg cells, yet striking differences
with respect to blood Treg cells. Differential expression
analysis revealed 309 transcripts consistently upregulated
in Treg cells from NSCLC and CRC tumors, but not in
other CD4+ T cells subpopulations or in tissue-resident
Treg cells. The intratumoral signature includes genes asso-
ciated with increased suppressor activity, such as the im-
mune checkpoints CTLA4, lymphocyte activation gene 3
(LAG3), and T-cell membrane protein 3 (TIM3). Three of
the most highly expressed signature genes, layilin (LAYN),
MAGE family member H1 (MAGEH1), and CCR8 (the
latter two were also identified as a unique feature of
tumor-infiltrating Treg cells by the Rudensky laboratory
[4]), were associated with a significant worsening of the 5-
year survival of both CRC and NSCLC patients. Finally,
the authors confirmed the expression signatures shared by
CRC- and NSCLC-infiltrating Treg cells via single-cell ana-
lysis and demonstrated that they are conserved across dif-
ferent metastatic and non-metastatic cancers.
Potential for new therapeutic strategies for cancer
immunotherapy
The presence of Treg cells in the tumor microenvironment
represents one of the main obstacles for successful cancer
immunotherapy. Since their immunosuppressive action is
exerted through different mechanisms, the selective deple-
tion of tumor-infiltrating Treg cells holds promise for
unleashing potent antitumor responses. These two re-
sources [4, 5] now provide the potential means for targeted
depletion of Treg cells. Both studies showed that CCR8 is
specifically expressed in tumor-infiltrating Treg cells in mul-
tiple tumor types, suggesting that CCR8 represents apromising target to selectively deplete Treg immunosup-
pressive activity in the tumor microenvironment.
The marked differences between tumor-resident and
blood-derived Treg cells reported in these studies high-
light the importance of assessing the phenotypes of
immune cells at the tumor site. The generation of add-
itional transcriptomic data from other tumor-infiltrating
immune cells would tremendously benefit the develop-
ment and optimization of computational approaches for
dissecting complex tumor–immune cell interactions [7],
and could contribute to the identification of novel mech-
anistic insights.
A number of questions remain unanswered and should
motivate further experimental and clinical studies. For
example, the mechanisms underlying the increased infil-
tration of Treg cells in aggressive cancers such as TNBC,
and the implications for cancer prognosis, remain elu-
sive. Furthermore, heterogeneity of tumor-infiltrating
Treg cells has not been addressed. It was shown recently
that distinct subpopulations of Treg cells contribute in
opposing ways to determining CRC prognosis: CRCs in-
filtrated with suppression-competent Treg cells had a
worse prognosis compared with CRCs infiltrated with
non-suppressive Treg cells [8]. Thus, additional studies
need to be carried out to validate this observation in
other cancer types. Finally, it should be noted that the
promising candidate for therapeutic targeting, CCR8, is
also expressed in cardiomyocytes and liver [9]; thus,
straightforward systemic treatment with CCR8 inhibitors
might cause serious immune-related adverse effects.
Still, the two studies highlight the importance of asses-
sing the phenotypes of immune cells specifically within
the tumor site. Further transcriptomic characterization
of tumor-infiltrating Treg cells in other cancers, as well
as other immunosuppressive cell populations, will be of
the utmost importance for the prevention of resistance
to cancer immunotherapies.Abbreviations
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